RCS - Diaceutics PLC - Diaceutics to attend Stifel Conference in NYC

DiaceuticsAnnouncement

30/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd9754Ua&default-theme=true

RNS Number : 9754U  Diaceutics PLC  30 November 2023

Diaceutics to attend Stifel and LSE 'Best of British' Conference in NYC

 

Belfast and London, 30 November 2023 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical and biotech industry, announces that
management will attend the Stifel 5(th) Annual 'Best of British' Discovery
Conference at the London Stock Exchange's NYC offices on 13 December 2023.

 

Enquiries:

 

 Diaceutics PLC  
 Peter Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Executive Officer Designate        investorrelations@diaceutics.com
 Nick Roberts, Chief Financial Officer 

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEFPAELDFAA